ArticleWorld journal of surgical oncology2016
Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
Article in World journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.BioMed research international · 2018Pooled it
- Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.BMC cancer · 2026Article
- Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.Cancers · 2022Review
- MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?Current genomics · 2020Review
- Article
- MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β receptor I ubiquitination.Molecular oncology · 2019Article
- Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.Journal of clinical medicine · 2019Review
- Retraction Note: Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.World journal of surgical oncology · 2019Article
- A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer.Carcinogenesis · 2019Article
- Review
- MicroRNA in Lung Cancer Metastasis.Cancers · 2019Review
- Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer.Journal of clinical medicine · 2019Article
- MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis.Cancer management and research · 2019Article
- Treatment of cancer cells with chemotherapeutic drugs results in profound changes in expression of genes encoding aldehyde-metabolizing enzymes.Journal of Cancer · 2019Article
- MicroRNA-195 as a diagnostic biomarker in human cancer detection: A meta-analysis.Oncology letters · 2018Article
- miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer.Cell death & disease · 2018Article
- Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.Clinical epigenetics · 2018Review
- Downregulation of serum miR-101 is associated with worse prognosis in non-small cell lung cancer.International journal of clinical and experimental pathology · 2018Article
- MicroRNA-195 inhibits epithelial-mesenchymal transition via downregulating CDK4 in bladder cancer.International journal of clinical and experimental pathology · 2018Article
- The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers.Oncotarget · 2017Article
Corrections and comments
- Retraction · 2019-07-10Euphemisms for Plagiarism · Plagiarism of/in Article ·
- Retracted
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, circulating microRNAs (miRNAs) have been reported to be stably detectable in plasma/serum and to function as potent biomarkers in various cancers. The aim of this study was to evaluate the expression level of plasma miRNA-195 in patients with non-small cell lung cancer (NSCLC) and investigate its diagnostic and prognostic value.
methodsQuantitative real-time PCR was performed to evaluate plasma miRNA-195 levels in 100 NSCLC patients and 100 healthy volunteers. The association between miRNA-195 expression and clinicopathological factors as well as the overall survival was analyzed. Receiver-operating characteristic (ROC) curve analysis was carried out to assess the potential value of plasma miRNA-195 for NSCLC diagnosis.
resultsPlasma miRNA-195 was downregulated in NSCLC patients compared with healthy controls (P < 0.001). Decreased plasma miRNA-195 expression was significantly associated with lymph node metastasis and advanced clinical stage. ROC curve analysis showed that plasma miRNA-195 was a useful marker for NSCLC diagnosis. Multivariate Cox regression analysis confirmed low plasma miRNA-195 expression as an independent unfavorable prognostic factor for NSCLC patients.
conclusionsThese findings indicate that plasma miRNA-195 might serve as a promising biomarker for the early detection and prognosis evaluation of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.